Regional Content Customized for Canada
This page contains IO Essentials resources that have been customized for use by the Canadian healthcare professional.
Stage II Melanoma Treatment Videos
In this video series, Dr. D. Scott Ernst, MD, FRCPC Head, Division of Medical Oncology and Professor of Medicine at the London Regional Cancer Program, discusses the use of treatments in patients with melanoma. The videos address whether to treat, the risks versus benefits of treatment and the differences between the stages IIA, B and C. The content is customized for Canada. This content was recorded in March 2024.
What is stage II melanoma?
Is stage II melanoma at high risk for coming back?
How is stage IIA melanoma treated?
How is stage IIB and C melanoma treated?
How do you weigh the benefits and risks of treatment versus no treatment?
What are the side effects of treatment?
New videos from the experts!
Sequencing of Therapies in Stage IV Melanoma
In this video series, Dr. Marcus Butler, Clinical Head of the Immune Monitoring Team at the Princess Margaret Cancer Centre, discusses sequencing strategies for Stage IV melanoma. The videos address strategies for neoadjuvant and adjuvant therapy, first-line and subsequent lines of therapy, single-agent and combination immunotherapy, BRAF-targeted therapy, the management of brain metastases, clinical trials, and management of refractory disease. The videos were recorded on August 17, 2023.
When should neoadjuvant or adjuvant therapy be considered in stage IV disease?
Which immunotherapy should be used for front-line BRAF wild-type patients?
Which combination should be used after progression post PD-1 therapy?
What is the role for BRAF-targeted therapy?
How should strategies be personalised for management of brain metastases?
Strategies for refractory disease
When should a clinical trial be considered?
New videos from oncology experts!
Immunotherapy Combination Therapy: Current and Emerging Approaches
In this video series, Bonnie Leung, MN-N (F)P, BC Cancer, Vancouver, discusses current and emerging perspectives on the use of combination immunotherapy in oncology. These videos, developed for the Canadian audience, discuss the rationale for combination therapy, the data supporting the combination approaches, patient selection for combination immunotherapy versus other options, managing the more complex side effects associated with this approach, as well as new strategies of combined immunotherapy. We hope that this content will be useful for you to select and manage the best immunotherapy regimens for your cancer patients.
Rationale for Combined Immunotherapy
What are the data to support the use of combination Immunotherapy?
Patient Selection for Combination Immunotherapy
Managing the Complex Adverse Effect Profile of Combination Immunotherapy
Emerging Strategies for Combination Immunotherapy
COVID-19 Vaccine Recommendations for IO Patients
In the following videos, Massey Nematollahi, RN, MScN, OCN, CON©, Immuno-Oncology Clinical Nurse Specialist at William Osler Health System in Brampton, Ontario, discusses the use of COVID-19 vaccines in patients with cancer, particularly in those receiving immune checkpoint inhibitors (ICIs). The content is customised for the Canadian region. This content was recorded on August 20, 2021 and is reflective of the vaccine approvals as of that date. For an updated list of the currently available vaccines approved in Canada, please click here: Canada – COVID19 Vaccine Tracker (trackvaccines.org)
1 Review of available COVID 19 vaccines
2 Timing of receipt of vaccines
3 COVID 19 vaccines and ICIs
4 Addressing frequently asked questions and myths about COVID 19 vaccines
5 Addressing COVID 19 vaccine hesitancy